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Osamu Iida, MD,a Yoshimitsu Soga, MD,b Yasutaka Yamauchi, MD,c Keisuke Hirano, MD,d
Daizo Kawasaki, MD,e Terutoshi Yamaoka, MD,f Mitsuyoshi Takahara, MD,g and
Masaaki Uematsu, MD, PhD,a Hyogo, Fukuoka, Yokohama, Matsuyama, and Osaka, Japan
Background: Prognosis of endovascular therapy (EVT) for isolated infrapopliteal lesions has not been adequately studied.
We investigated and risk-stratiﬁed long-term prognosis after EVT for critical limb ischemia (CLI) attributable to isolated
infrapopliteal lesions.
Methods: Between March 2004 and October 2010, 884 patients (1057 limbs) with CLI attributable to isolated infra-
popliteal lesions who underwent EVT with angioplasty alone were enrolled. Outcome measures were freedom from major
adverse limb events with perioperative death (MALEDPOD) and amputation-free survival. Cox proportional hazards
models were used to assess independent predictors for these outcomes.
Results: Freedom from MALEDPOD was 82 ± 1% and 74 ± 2% at 1 and 5 years, respectively. Risk factors associated with
MALEDPODwere age$80 years (adjusted hazard ratio [HR], 0.4; P < .001), nonambulatory status (HR, 2.0; P < .001),
albumin <3.0 g/dL (HR, 1.4; P < .0001), Rutherford 6 (HR, 2.2; P < .001), C-reactive protein $3.0 mg/dL (HR, 2.1;
P < .001), and below-the-ankle disease (HR, 2.0; P < .001). One- and 5-year amputation-free survival was 71 ± 2% and
38 ± 3%, respectively. Risk factors associated with major amputation/mortality were nonambulatory status (adjusted HR,
2.1; P < .001), body mass index <18.5 kg/m2 (HR, 1.4; P[ .02), albumin <3.0 g/dL (HR, 1.8; P < .0001), end-stage
renal disease (HR, 1.4; P [ .004), ejection fraction <50% (HR, 1.6; P < .001), Rutherford 6 (HR, 1.9; P < .001), C-
reactive protein $3.0 mg/dL (HR, 1.7; P < .0001), and below-the-ankle disease (HR, 1.8; P < .001). In patients with
more than four risk factors, both end points at 1 year were below the 71% suggested efﬁcacy objective performance goal.
Conclusions: Long-term clinical outcomes were acceptable after EVT for patients with CLI due to pure isolated
infrapopliteal lesion. Risk stratiﬁcation by baseline characteristics is useful in estimating long-term prognosis. (J Vasc
Surg 2013;57:974-81.)Developments in endovascular therapy (EVT) have
raised expectations for improvement of the traditionally
poor prognosis of critical limb ischemia (CLI) associated
with infrapopliteal lesions.1-4 In particular, primary angio-
plasty is now widely used for the treatment of infrapopliteal
arterial lesions in CLI patients; according to the latest
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acceptable therapeutic modality to treat patients with
CLI attributable to infrapopliteal lesions because of its
favorable clinical outcome at a lower procedural cost
compared with open bypass therapy (BSX).5-8
Despite its wide acceptance, the prognosis of EVT for
isolated infrapopliteal lesions has not been adequately
studied. To this end, outcomes combining life and limb
prognosis, the commonest of which are amputation-free
survival (AFS) and freedom from major adverse limb events
(MALE) including amputation or major reintervention
or perioperative death (POD), are regarded as inherent
measures of prognostic effectiveness for revascularization
of CLI patients. Moreover, based on analysis of three major
randomized trials, Conte and colleagues have proposed
a 71% rate as an objective performance goal (OPG) for
both AFS and freedom from MALEþPOD in catheter-
based therapies.9
Prognosis of CLI patients undergoing EVT for pure
isolated infrapopliteal lesions, therefore, would need to be
compared against the aforementioned reference goals.
However, common comorbidities in CLI patients pro-
foundly inﬂuence prognostic outcomes.10 Diabetes melli-
tus (DM) and end-stage renal disease (ESRD), for
instance,11 are both present in high proportions and are
well known as independent predictors for poor prognosis
in CLI patients; they are also independent risk factors for
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infrapopliteal lesions.12 Considerable inter-patient variation
in prognosis of CLI patients with infrapopliteal lesion would
be expected with poorer or better prognosis respectively
in the presence or absence of particular comorbidities.
Stratiﬁcation of patients according to their prognostic risk,
therefore, would be clinically relevant.
The aims of our current study were to (1) investi-
gate prognostic risk factors associated with AFS and
MALEþPOD in CLI patients undergoing EVT for pure
isolated infrapopliteal arterial lesions; and (2) assess the
prognostic outcomes of these patients after stratiﬁcation
according to the number of risk factors present.METHODS
Participants. We retrospectively analyzed our pro-
spectively maintained database including data on 2519
limbs in 2141 consecutive CLI patients who underwent
EVT from April 2004 to June 2011 and who consented
to follow-up at each of the 11 participating cardiovascular
and vascular centers. To elucidate long-term clinical efﬁ-
cacy and stratify the risk for EVT outcomes, this study
included patients with CLI attributable to pure isolated
infrapoliteal lesions who underwent endovascular recon-
struction. We excluded patients with involved popliteal and
above popliteal revascularization. During this period,
patients with CLI attributable to infrapopliteal lesions
combined with either femoropopliteal lesions (47%, 1198
limbs in 1025 patients) or aortoiliac-femoropopliteal
lesions (10%, 264 limbs in 232 patients) were excluded
from this study. We also excluded 170 patients considered
to be poor candidates for both forms of revascularization
because of severe comorbidities and impairment at the
functional, cognitive, and/or social (no family or profes-
sional career) levels; who refused revascularization; or who
presented with acute limb ischemia requiring emergent
revascularization or with functionally unsalvageable limbs.
Finally, 1057 limbs from 884 consecutive CLI patients
suffering from rest pain attributable to ischemia (Ruth-
erford 4), or limb-threatening nonhealing ulceration/
gangrene (Rutherford 5 or 6) attributable to pure isolated
infrapopliteal lesions were included. During the study
period, 375 CLI patients were treated with crural BSX by
a vascular surgeon. Forty-four percent of limbs (n ¼ 465)
with isolated infrapopliteal lesion overlapped with
a previous study.10 The study protocol was developed in
accordance with the Declaration of Helsinki and approved
by the ethics committee of each participating hospital. This
study was registered in the University Hospital Medical
Information Network Clinical Trial Registry, which was
approved by the International Committee of Medical
Journal Editors (No UMIN000007016, Japanese Below-
the-Knee Artery Treatment Registry II). All patients gave
written informed consent prior to revascularization.
Study protocol. The study protocol was reported
previously.10 Brieﬂy, lower limb severity was hemody-
namically assessed by the ankle-brachial index and skinperfusion pressure (SPP). Lower limb arteries were rou-
tinely evaluated by duplex ultrasound, and presence of
infrapopliteal lesions was assessed by digital subtraction
angiography before revascularization. A group of vascular
specialists including vascular surgeons and radiologists
judged whether EVT was indicated for each patient. All
endovascular procedures were conducted under local
anesthesia. EVT was indicated when the lesion showed
>75% diameter stenosis on diagnostic angiography and was
hemodynamically signiﬁcant. Selection of EVT approach
was at operator’s discretion. An antegrade approach with
a 4F sheath from the ipsilateral common femoral artery was
most commonly used. After inserting the sheath, unfrac-
tionated heparin (5000 U) was routinely injected into the
artery. A 0.014-inch guidewire was advanced into the
culprit lesion, and an optimally sized balloon catheter
was introduced. Vessel diameter and lesion length were
visually assessed using the balloon catheter as reference. A
100-mm- or 120-mm-long balloon (Shiden; Kaneka
Medix Corporation, Osaka, Japan, or Amphillion; Med-
tronic, Minneapolis, Minn) was commonly used and
balloon inﬂation was held at nominal pressure for at least
180 seconds to avoid ﬂow limiting dissection. Bare-metal
or drug-eluting stents and atherectomy devices were not
used because of unavailability in Japan. Target lesion was
chosen based on lesion and limb severity. In patients with
tissue loss, target lesion was decided by the angiosome
concept,13 and easily treatable lesions were commonly
selected in patients with rest pain. Dual antiplatelet therapy
(aspirin at 100 mg/d and ticlopidine at 200 mg/d or cil-
ostazol at 200 mg/d) was started at least 1 week prior to
EVT and continued lifelong. Antibiotics were routinely
administered if the ulcer was complicated with limb
threatening severe infection as judged by a plastic surgeon
who in these cases evaluated and managed the ulcer using
the TIME concept (Tissue, Infection, Moisture Imbalance,
Edge of Wound).14
All patients were followed up at 1 week, and at 1, 3,
and 6 months after revascularization, and thereafter
every 3 months. If a patient did not come to the hospital,
telephone calls were made to check limb status and the
patient’s general health. At the time of follow-up, noninva-
sive testing, including ankle-brachial index, SPP, and
duplex, was routinely conducted.
Study outcomes. The outcome measures were
freedom from MALEþPOD and AFS. We also assessed
30-day mortality and major amputation rate as safety
outcomes, as proposed by the Society of Vascular Surgery.9
Deﬁnitions. The deﬁnitions of lower limb severity and
the criteria for diagnosis of atherosclerosis risk factors have
been reported previously.11 Critical ischemic limb was
deﬁned in accordance with TransAtlantic Inter-Society
Consensus (TASC) guideline.2 When these measurements
could not be obtained because of intractable rest pain or
a noncompressible artery secondary to severe calciﬁcation,
the SPP was measured; an SPP less than 40 mm Hg was
deﬁned as indicating a critical ischemic limb. Coronary
artery disease and cerebrovascular disease was deﬁned as
Table I. Baseline characteristics of study population
Variables
Patients status (n ¼ 884)
Age, years 71 6 10
Male sex 69% (612)
BMI 22 6 3
Albumin, g/dL 3.5 6 0.6
Nonambulatory 38% (338)
Risk factors
Hypertension 73% (647)
Hyperlipidemia 61% (540)
Diabetes mellitus 71% (627)
Current smoking 36% (318)
ESRD (Cr $2.0 mg/dL) 64% (564)
EF, % 59 6 14
Lower limb and lesion status
(n ¼ 1057)
Tissue loss (Rutherford 5, 6) 74% (781)
Rutherford 6 19% (195)
CRP, mg/dL 2.7 6 4.2
ABI before angioplasty 0.81 6 0.25
SPP at dorsalis pedis side/plantar
side, mmHg
32 6 17/35 6 19
TASC A/B/C/D 3% (32)/1% (13)/7%
(67)/90% (945)
Lesion calciﬁcation 65% (682)
Target lesion length, mm 190 6 96
Number of BTK run-offs before
angioplasty/after angioplasty
0.50 6 0.68/1.8 6 0.8
BA disease before angioplasty 59% (627)
ABI, Ankle-brachial index; BA, below-the-ankle; BTK, below-the-knee;
BMI, body mass index; Cr, creatinine; CRP, C-reactive protein; EF, ejec-
tion fraction; ESRD, end-stage renal disease; TASC, TransAtlantic Inter-
Society Consensus; SPP, skin perfusion pressure.
Number of BTK run-offs before angioplasty was deﬁned as the number of
patent run-offs to the ankle.
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history of any revascularization. Below-the-ankle (BA)
disease was deﬁned as presence of a diseased arterial lesion
at the dorsalis pedis or plantar artery. Treated lesion with
widest limb perfusion area was identiﬁed as target lesion in
this study. EVT procedural success was deﬁned as obtain-
ing one straight-line ﬂow to the foot without occurrence of
any ﬂow limiting dissection. Reintervention including
repeat angioplasty or bypass graft procedures were indi-
cated for limbs with recurrent symptoms accompanied by
recurrent stenosis greater than 50% as measured by duplex
ultrasound or digital subtraction angiography. Perioper-
ative death was deﬁned as death occurring within 30 days.
MALE was deﬁned as major amputation or any major
reintervention during the study period. Major reinterven-
tion included new bypass graft, jump, interposition graft
revision, or the use of thrombectomy or thrombolysis
in stents upon loss of primary assisted patency. Minor
reintervention was deﬁned as endovascular procedures
(percutaneous transluminal angioplasty, atherectomy,
stenting) without thrombectomy or thrombolysis, and
minor surgical revisions (patch angioplasty). Major ampu-
tation was deﬁned as surgical excision of the limb above the
ankle. Any amputation at or distal to the Lisfranc level was
not considered a limb salvage failure. Amputation data
were obtained through outpatient clinic follow-up contact.
AFS was deﬁned as major amputation or death.
Statistical analysis. Data are presented as mean 6 SD
for continuous variables and as percentages for dichoto-
mous variables unless mentioned otherwise. Prognostic
outcomes were assessed with the Kaplan-Meier method,
and differences among groups with the log-rank test when
necessary; their 1-year incidence is reported with the
respective SE. Univariate Cox proportional hazards reg-
ression model was used to determine the unadjusted
association of each variable with the outcomes. The
statistically signiﬁcant variables in the univariate analyses
were entered into multivariate models to assess their
independent impact on the outcome. We developed two
multivariate models for each outcome: models into which
all the signiﬁcant explanatory variables in prior univariate
models were entered (model 1), and those into which the
variables were entered using a stepwise method (model 2).
Hazard ratios (HRs) and 95% conﬁdence intervals (CIs)
are reported. We subsequently conducted risk stratiﬁcation
analysis for each outcome using a simple score based on the
number of independent variables. A P value of <.05 was
considered signiﬁcant. Statistical analyses were performed
using SPSS v. 15.0J (SPSS Inc, Chicago, Ill).
RESULTS
Table I shows baseline characteristics of the study pop-
ulation. Notable baseline characteristics included mean
patient age of 71 6 10 years, and high prevalence of DM
(71%; 627/884) and ESRD on dialysis (62%; 546/884).
Regarding limb status, 74% (781/1057) of limbs were
complicated with tissue loss. Ninety percent of lesions
were TASC 2000 D, and BA disease, deﬁned as presenceof a diseased arterial lesion at the dorsalis pedis or plantar
artery, was observed in 63% of cases. Follow-up period
was 17 6 17 months (1.4 6 1.4 years), and 330 of the
884 patients underwent major amputations or mortality,
whereas MALEþPOD was seen with 191 of 1057 limbs.
Thirty-day safety outcomes. Procedural success,
deﬁned as obtaining one straight-line ﬂow to the foot,
was achieved in 95% (1009/1057) of limbs. Rate of peri-
operative death following EVT was 3% (26/884); 58%
(15/26) of patients died from cardiovascular disease within
30 days. Cardiac death was the most frequent cause of
death (50%; 13/26) in these CLI patients. In 31% (8/26),
cause of death was attributed to infectious disease. Major
amputation was conducted in 1% (14/1057) of limbs
within 30 days.
Freedom from MALEDPOD and its associated
factors (Fig 1, A and Table II). Freedom from
MALEþPOD was 82 6 1%, 79 6 2%, and 74 6 2% at 1,
3, and 5 years, respectively. Predictors for MALEþPOD
were age $80 years (HR, 0.4; 95% CI, 0.3-0.7; P < .001)
nonambulatory status (HR, 2.0; 95% CI, 1.5-2.7; P <
.001), albumin <3.0 g/dL (HR, 1.4; 95% CI, 1.0-2.0;
P < .0001), Rutherford 6 (HR, 2.2; 95% CI, 1.6-3.1; P <
.001), CRP $ 3.0 mg/dL (HR, 2.1; 95% CI, 1.6-3.1; P <
Fig 1. A, Freedom from major adverse limb events with perioperative death (MALEþPOD) after angioplasty for 1057
critical ischemic limbs because of pure isolated infrapopliteal lesions. Overall freedom from MALEþPOD was 82 ± 1%,
79 ± 2%, and 74 ± 2% at 1, 3, and 5 years, respectively. B, Amputation-free survival (AFS) after angioplasty for 884
patients with critical limb ischemia (CLI) due to pure isolated infrapopliteal lesions. AFS was 71 ± 2%, 51 ± 2%, and
37 ± 3% at 1, 3, and 5 years, respectively. SE, Standard error.
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Freedom from MALEþPOD was stratiﬁed according to
number of these risk factors (Fig 2). Note that since the
HR of age $80 years was smaller than 1, we regarded
age <80 years as a risk factor in the risk stratiﬁcation.
Freedom from MALEþPOD was lower in the higher risk
groups (1-year rates by number of risk factors: 0-1, 946 1%;
2, 89 6 2%; 3, 80 6 3%; 4, 63 6 5%; and 5-6, 40 6 6%,
respectively; P < .001).
AFS and its associated factors (Fig 1, B and
Table III). Fig 1, B shows 5-year AFS. AFS was 71 6 2%,
51 6 2%, and 37 6 3% at 1, 3, and 5 years, respectively.
Results of the multivariate Cox proportional hazard
regression analysis for AFS are shown in Table III. Non-
ambulatory status (HR, 2.1; 95% CI, 1.7-2.7; P < .001),
BMI <18.5 kg/m2 (HR, 1.4; 95% CI, 1.1-1.8; P ¼ .02),
albumin <3.0 g/dL (HR, 1.8; 95% CI, 1.4-2.3; P <
.0001), ESRD (HR, 1.4; 95% CI, 1.1-1.8; P ¼ .004),
ejection fraction <50% (HR, 1.6; 95% CI, 1.2-2.0; P <
.001), Rutherford 6 (HR, 1.9; 95% CI, 1.4-2.4; P < .001),
CRP$3.0 mg/dL (HR, 1.7; 95% CI, 1.3-2.2; P < .0001),
and BA disease (HR, 1.8; 95% CI, 1.4-2.3; P < .001) were
associated with major amputation and mortality. Fig 3
shows the stratiﬁcation of AFS according to number of
these risk factors. The AFS was lower in the higher risk
groups (1-year rates by number of risk factors: 0-1, 90 6
2%; 2, 83 6 3%; 3, 70 6 4%; 4, 59 6 5%; and 5-8, 25 6
4%, respectively; P < .001).
Overall survival, limb salvage, and freedom from
any reintervention rate up to 5 years (Supplementary
Figs 1-3, online only). Overall survival was 78 6 2%,
59 6 2%, and 43 6 3% at 1, 3, and 5 years, respectively.Limb salvage rate was 89 6 1%, 86 6 1%, and 85 6 2%
at 1, 3, and 5 years, respectively. Almost all major amputa-
tions were performed before 1 year. Freedom from any
reintervention including minor or major reintervention
was 66 6 2%, 52 6 2%, and 47 6 3% at 1, 3, and 5 years,
respectively. During the chronic phase, 5.4% (57/1057) of
limbs underwent surgical conversion after initial EVT and
re-angioplasty was done for 31% (328/1057) of limbs.
Finally, MALE-free survival is shown in Supplementary
Fig 4 (online only). MALE-free survival was 66 6 2%,
49 6 2%, and 33 6 3% at 1, 3, and 5 years, respectively.
DISCUSSION
In this multicenter study including a large number of
patients with CLI attributable to pure isolated infrapopli-
teal lesions, freedom from MALEþPOD and AFS rate at
5 years after infrapopliteal angioplasty was 74 6 2% and
376 3%, respectively. After risk stratiﬁcation analysis based
on risk score assignment according to number of predictive
end points, freedom from MALEþPOD and AFS were
lower in the higher-score groups. In the clinical setting,
risk stratiﬁcation based on these predictors before catheter
revascularization would be useful in estimating future
adverse outcome. To the best of our knowledge, this is
the ﬁrst study to assess risk stratiﬁcation of standard
outcomes following angioplasty in patients with CLI due
to pure isolated infrapopliteal lesions.
DM and ESRD, whose prevalence has dramatically
increased worldwide, have been reported to signiﬁcantly
affect the development of CLI and to be risk factors for
atherosclerotic involvement of infrainguinal, especially
infrapopliteal, arteries. From recent trials, patients with
Table II. Association of baseline characteristics with MALE and POD
Univariate model Multivariate model 1 Multivariate model 2
Patients status
Age $80 years 0.5 (0.3, 0.7)a 0.5 (0.3, 0.8)a 0.4 (0.3, 0.7)a
Male sex 0.9 (0.7, 1.2)a e e
BMI <18.5 kg/m2 0.9 (0.6, 1.3) e e
Albumin <3.0 g/dL 2.4 (1.7, 3.3)a 1.5 (1.0, 2.1)a 1.4 (1.0, 2.0)a
Nonambulatory 2.6 (1.9, 3.4)a 1.9 (1.4, 2.6)a 2.0 (1.5, 2.7)a
Risk factors
Hypertension 0.8 (0.6, 1.1) e e
Hyperlipidemia 0.9 (0.6, 1.2) e e
Diabetes mellitus 1.3 (1.0, 1.9) e e
Current smoking 1.0 (0.8, 1.4) e e
End-stage renal disease 1.5 (1.1, 2.1)a 1.3 (1.0, 1.9) e
EF <50% 1.8 (1.3, 2.4)a 1.2 (0.9, 1.7) e
Lower limb status
Rutherford 6 3.7 (2.8, 5.0)a 2.2 (1.6, 3.1)a 2.2 (1.6, 3.1)a
CRP $3.0 mg/dL 3.4 (2.6, 4.6)a 2.1 (1.5, 2.9)a 2.1 (1.6, 3.0)a
TASC D 1.5 (0.9, 2.7) e e
BTK run-offs (vs 2 run-offs) 1.0 (Ref) e e
1 run-off 1.0 (0.5, 1.8) e e
0 run-off 1.0 (0.6, 1.8) e e
BA disease 2.1 (1.5, 2.9)a 2.0 (1.4, 2.8)a 2.0 (1.4, 2.8)a
BA, Below-the-ankle; BTK, below-the-knee; BMI, body mass index; CI, conﬁdence interval; CRP, C-reactive protein; EF, ejection fraction; ESRD, end-stage
renal disease; HR, hazard ratio; MALE, major adverse limb events; POD, perioperative death; TASC, TransAtlantic Inter-Society Consensus.
Data are HRs and 95% CIs.
aP < .05.
Fig 2. Risk stratiﬁcation of major adverse limb events with peri-
operative death (MALEþPOD) based on multivariable logistic
analysis. Patients were assigned to groups based on the number of
multivariable risk factors. Freedom from MALEþPOD was lower
in the higher-risk groups (1-year rates by number of risk factors:
94% for 0-1; 86% for 2; 75% for 3; 58% for 4; and 18% for 5 factors,
respectively; P < .001).
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appear to have more extensive distal disease including
BA disease, poor initial pedal runoff leading to high
incidence of major amputation, and severe comorbidities
precluding surgical bypass compared with those patients
with CLI attributable to multilevel disease.3 Therefore,CLI attributable to pure isolated infrapopliteal lesion has
been considered the most severe form of peripheral artery
disease (PAD) in the overall population. Recently, because
of the evolution of techniques and the availability of dedi-
cated materials, the endovascular approach demonstrated
improved clinical outcomes and, therefore, had been
considered as ﬁrst-line therapy in patients with CLI.5,6 A
recent meta-analysis of infrapopliteal angioplasty for the
treatment of CLI by Romiti et al showed a limb salvage
rate of 86% and a patient survival rate of 98%, which
were comparable to those of bypass surgery.4 Another
study using propensity matching analysis to decrease
confounder bias reported similar 5-year limb salvage and
AFS rates between endovascular and surgical procedures
for CLI attributable to infrainguinal lesions.7 Therefore,
infrapopliteal angioplasty is considered an acceptable
therapeutic modality to treat patients with CLI attributable
to infrapopliteal lesions, and it is most widely used in
clinical practice. However, prognostic factors, including
those derived from detailed laboratory examination,
cardiac function evaluation, and angiographic features of
infrapopliteal arteries, have not been systematically studied.
From analysis of three major randomized trials, age
over 80 years and tissue loss, and presence of DM were
associated with MALEþPOD. In the present study,
after multivariate analysis, age over 80 years, nonambula-
tory status, albumin <3.0 g/dL, ejection fraction <50%,
Rutherford 6, CRP >3.0 mg/dL, and BA disease were
independently associated with the outcome. However,
the opposite results were obtained when studying the
inﬂuence of patient age on MALEþPOD. We performed
Fig 3. Risk stratiﬁcation of amputation-free survival (AFS) based
on multivariable logistic analysis. Patients were assigned to groups
based on the number of multivariable risk factors. AFS was lower
in the higher-risk groups (1-year rates by number of factors: 90%
for 0-1; 82% for 2; 71% for 3; 57% for 4; 38 % for 5; and 3% for 6-8
factors, respectively; P < .001).
Table III. Association of baseline characteristics with major amputation and mortality
Univariate model Multivariate model 1 Multivariate model 2
Patients status
Age $80 years 1.1 (0.8, 1.4) e e
Male sex 0.9 (0.7, 1.1) e e
BMI <18.5 kg/m2 1.6 (1.2, 2.1)a 1.4 (1.0, 1.8)a 1.4 (1.1, 1.8)a
Albumin <3.0 g/dL 2.8 (2.2, 3.5)a 1.8 (1.4, 2.3)a 1.8 (1.4, 2.3)a
Nonambulatory 3.0 (2.4, 3.8)a 2.1 (1.7, 2.7)a 2.1 (1.7, 2.7)a
Risk factors
Hypertension 1.0 (0.8, 1.3) e e
Hyperlipidemia 0.7 (0.5, 0.8)a 0.8 (0.7, 1.0) e
Diabetes mellitus 0.9 (0.7, 1.2) e e
Current smoking 0.9 (0.7, 1.2) e e
ESRD 1.5 (1.2, 1.9)a 1.4 (1.1, 1.8)a 1.4 (1.1, 1.8)a
EF <50% 2.0 (1.6, 2.6)a 1.6 (1.2, 2.0)a 1.6 (1.2, 2.0)a
Lower limb status
Rutherford 6 2.9 (2.3, 3.7)a 1.9 (1.4, 2.4)a 1.9 (1.4, 2.4)a
CRP $3.0 mg/dL 2.7 (2.1, 3.2)a 1.7 (1.3, 2.2)a 1.7 (1.3, 2.2)a
TASC D 2.0 (1.2, 3.2)a 1.7 (1.0, 2.8) e
BTK run-offs (vs 2 run-offs) 1.0 (Ref) e e
1 run-off 1.2 (0.9, 2.2) e e
0 run-off 1.4 (0.7, 1.9) e e
BA disease 1.9 (1.4, 2.4)a 1.8 (1.4, 2.3)a 1.8 (1.4, 2.3)a
BA, Below-the-ankle; BMI, body mass index; BTK, below-the-knee; CI, conﬁdence interval; CRP, C-reactive protein; EF, ejection fraction; ESRD, end-stage
renal disease; HR, hazard ratio; TASC, TransAtlantic Inter-Society Consensus.
Data are HRs and 95% CIs.
aP < .05.
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teristics of patients aged over 80 years and those aged
less than 80 years. As a result, we found that DM and
dialysis, both of which strongly affect survival and major
amputation rate, were more prevalent in patients aged
less than 80 years than those aged over 80 years. Younger
CLI patients had more advanced atherosclerosis becauseof more frequent presence of comorbidities, and more
severe infrapopliteal artery lesions subsequently lead to
worse limb outcomes. Cardiac function and BMI <18.5
were not predictors for MALEþPOD. In the TASC guide-
line, cardiac failure or poor nutritional status were reported
as negative predictors for wound healing status and should
be evaluated and treated appropriately. However, in this
study, the latter factors did not appear to signiﬁcantly affect
limb prognosis, and we posit that patients with these risk
factors died before they could undergo major amputation
or major reintervention. MALE has several limitations as
an end point and has been reconsidered as such in the
era of endovascular treatment. Also, an end point including
complete wound healing might be preferable as limb end
point after revascularization.
Conte et al identiﬁed that two clinical factors, namely
age over 80 years and presence of tissue loss, affect AFS. In
the current study, we found that nonambulatory status,
BMI <18.5, albumin <3.0 g/dL, end-stage renal disease,
ejection fraction <50%, Rutherford 6, CRP >3.0 mg/dL,
and BA disease were independently associated with AFS.
Nonambulatory status indicates impaired ADLs, whereas
BMI<18.5 and albumin<3.0 g/dL suggest poor nutrition.
These three variables can be regarded as general status
factors. Contrary to data derived from the analysis performed
by Conte et al, age over 80 years was not an AFS predictor in
this study. In younger CLI patients, more advanced system-
atic atherosclerosis and more severe infrapopliteal artery
lesions were independent factors for MALE and also, in
general, older age was a risk factor for survival. AFS is
a combined end point including survival and amputation,
which probably offsets patient longevity and limb prognosis.
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mg/dL are likely to reﬂect substantial inﬂammation often
accompanying infection. Therefore, CRP level, as well as
Rutherford 6, seems to reﬂect limb status. BA disease is an
anatomic feature that often remains unimproved even after
intensive interventions includingEVT. Althoughwe have re-
ported that BA runoff plays an important role as the outﬂow
vessel affecting vessel patency after infrapopliteal angioplasty,
BA disease was found as a novel predictive factor for AFS,
and we posit that BA disease negatively affects vessel patency
leading to high occurrence of reintervention and major
amputation. The observation that general status factors,
limb status factors, and anatomic factors were independently
associated with AFS is not only of pathogenetic but also of
clinical interest, and suggests that the management of CLI
patients requires systemic evaluations in addition to local
treatment.
Regarding efﬁcacy of infrapopliteal angioplasty, overall
1-year AFS was 71%, which was equivalent to the results pre-
sented by Conte et al.9 Also, after risk stratiﬁcation, patients
with more than four predictors did not meet the 71% OPG
for 1-year AFS in catheter-based therapies. In terms of
freedom for MALEþPOD, the 1-year result of 81%
surpasses the OPG of 71%. In this study, major
reintervention did not include re-endovascular procedure;
hence, a better outcome was obtained. Limbs with more
than four predictors did not meet the 71% OPG for 1-year
AFS in catheter-based therapies. Finally, preprocedure strat-
iﬁcation of outcomes as derived from this study plays an
important role in therapeutic modality decision making.
Limitations. This was a retrospective and nonrandom-
ized study despite use of a prospectively maintained data-
base with a large number of consecutive CLI patients
with pure isolated infrapopliteal lesions. Patients consid-
ered unsuitable for revascularization or treated with BSX
were not managed by the physicians involved in the study
and, therefore, data on them were not collected and
analyzed. In addition, the actual number of patients with
completely healed wounds was not determined. Selection
of medication, especially of antiplatelet therapy, was at
the physicians’s discretion, leading to possible selection
bias. Although most patients were treated as part of an
endovascular-ﬁrst approach, some were referred for an
endovascular procedure because of the lack of bypass
target, lack of adequate vein conduit, and severe comor-
bidities precluding surgical bypass surgery. Therefore,
a heterogeneous patient population with different comor-
bidities and disease distribution was included in this study.
However, in the clinical setting, CLI attributable to pure
isolated infrapopliteal lesion is the most severe form in the
PAD population, and infrapopliteal angioplasty has been
most widely used for treatment of CLI patients. Overall
AFS rate at 1 year in this study was 71%, which was
comparable to the OPG deﬁned by Conte et al, doc-
umenting satisfactory results in this setting with only
traditional plain angioplasty. Several clinical, limb, and
anatomic status factors were associated with prognosis after
infrapopliteal angioplasty, and this could simplify theestimation of future AFS occurrence after an endovascular
approach. Also, risk stratiﬁcation for adverse outcomes
would be essential in endovascular revascularization, as it
may inform the decision-making process. These results are
in good agreement and match our daily clinical practice.
The results, however, cannot be generalized to surgical
intervention. Newer stratiﬁcation in the era of next-
generation devices for infrapopliteal intervention warrants
further prospective investigation against bypass results.
CONCLUSIONS
Long-term clinical outcomes were acceptable after
EVT with angioplasty for patients with CLI attributable
to pure isolated infrapopliteal lesions. Risk stratiﬁ-
cation based on outcome predictors allows estimation
before catheter revascularization of future occurrence of
MALEþPOD and AFS in CLI patients attributable to
pure infrapopliteal lesions.
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Supplementary Fig 1 (online only). Overall survival after
angioplasty for the 884 patients with critical limb ischemia (CLI)
because of pure isolated infrapopliteal lesions. Overall survival was
78 ± 1%, 59 ± 2%, and 43 ± 2% at 1, 3, and 5 years, respectively.
SE, Standard error.
Supplementary Fig 2 (online only). Limb salvage rate after
angioplasty in 1057 critical ischemic limbs. Limb salvage rate was
89 ± 2%, 86 ± 2%, and 85 ± 2% at 1, 3, and 5 years, respectively.
Almost all major amputations were performed before 1 year. SE,
Standard error.
Supplementary Fig 3 (online only). Freedom from any rein-
tervention. Freedom from any reintervention including minor or
major reintervention was 66 ± 1%, 56 ± 1%, and 47 ± 2% at 1, 3,
and 5 years, respectively. SE, Standard error.
Supplementary Fig 4 (online only). Major adverse limb event
(MALE)-free survival. MALE-free survival was 66 ± 2%, 49 ± 2%,
and 33 ± 3% at 1, 3, and 5 years, respectively. SE, Standard error.
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